|
| Status |
Public on May 28, 2020 |
| Title |
RNA-seq of MV-4-11 or THP-1 cells treated with LSD1 inhibitor INCB059872 |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
INCB059872 is a selective irreversible inhibitor of Lysine-Specific Demethylase 1 (LSD1) that is in phase 1 clinical trials in hematopoietic malignancies. LSD1 inhibition can induce differentiation of acute myeloid leukemia (AML), and here we have used RNA-seq to measure the transcriptional changes caused by INCB059872 in two AML cell lines.
|
| |
|
| Overall design |
Cells were treated (in duplicate) for 3hr or 24hr with INCB059872 before extracting RNA for polyA-enriched RNA-seq.
|
| |
|
| Contributor(s) |
Johnston G, Hiebert S |
| Citation(s) |
32422235 |
| |
| Submission date |
Feb 11, 2020 |
| Last update date |
May 28, 2020 |
| Contact name |
Scott Hiebert |
| Organization name |
Vanderbilt University
|
| Street address |
2220 Pierce Ave.
|
| City |
Nashville |
| State/province |
TN |
| ZIP/Postal code |
37232 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL21290 |
Illumina HiSeq 3000 (Homo sapiens) |
|
| Samples (14)
|
|
| Relations |
| BioProject |
PRJNA606049 |
| SRA |
SRP248224 |
Less...
More...